Ignite Creation Date:
2024-10-26 @ 3:43 PM
Last Modification Date:
2024-10-26 @ 3:43 PM
Study NCT ID:
NCT06644755
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-04
Brief Title:
First-in-Human Trial of DS-2243a in Participants With Advanced Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Phase 1 Open-Label Multicenter First-In-Human Trial of Ds-2243a in Participants With Advanced Solid Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This 2-part study will evaluate safety tolerability and clinical efficacy of DS-2243a as a treatment for participants with advanced solid tumors
Detailed Description:
This is a global multicenter open-label first-in-human Phase 1 trial of DS-2243a as a treatment for locally advanced or metastatic synovial sarcoma SS myxoidround cell liposarcoma MRCLS squamous cell carcinoma type non-small cell lung cancer Sq-NSCLC adenocarcinoma type non-small cell lung cancer Ad-NSCLC or urothelial carcinoma UC participants with HLA-A2 andor NY-ESO positive The trial consists of 2 parts the Dose Escalation Part Part 1 and the Dose Expansion Part Part 2
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None